NCT05949125View on ClinicalTrials.gov

Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies

PHASE1RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 3, 2024

Primary Completion Date

May 31, 2027

Study Completion Date

January 31, 2028

Conditions
Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia Refractory
Interventions
OTHER

Cyclophosphamide (Non-IMP, Lymphodepletion)

Intravenous infusion over 3 days (d-5 to d-3)

OTHER

Fludarabine (Non-IMP, Lymphodepletion)

Intravenous infusion over 3 days (d-5 to d-3)

DRUG

R-TM123

Intravenous infusion over 20 days

DRUG

Allo-RevCAR01-T

Allo-RevCAR01-T will be administered as IV infusion on Treatment day 1.

Trial Locations (11)

1081

NOT_YET_RECRUITING

Amsterdam University Medical Center, Amsterdam

3015

RECRUITING

Erasmus University Medical Center, Rotterdam

9700

NOT_YET_RECRUITING

University Medical Center Groningen (UMCG), Groningen

13353

RECRUITING

Charité Universitätsmedizin Berlin, Berlin

35032

RECRUITING

Universitätsklinikum Marburg, Marburg

50937

RECRUITING

Universitätsklinikum Köln, Cologne

81377

RECRUITING

Klinikum der Universität München, Munich

89081

RECRUITING

Universitätsklinikum Ulm, Ulm

97080

RECRUITING

Universitätsklinikum Würzburg, Würzburg

01307

RECRUITING

Universitätsklinikum Dresden, Dresden

Unknown

RECRUITING

Medizinische Hochschule Hannover, Hanover

All Listed Sponsors
collaborator

Allucent (NL) BV

UNKNOWN

lead

AvenCell Europe GmbH

INDUSTRY